Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KTTA Pasithea Therapeutics Corp.

Trading 06-10 12:11:30 EDT

0.5698

-0.0102

-1.76%

High0.5817	Low0.5600	Vol84.55K
Open0.5600	D1 Closing0.5800	Amplitude3.74%
Mkt Cap19.04M	Tradable Cap5.81M	Total Shares33.41M
T/O48.55K	T/O Rate0.83%	Tradable Shares10.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.5698,"timestamp":1781107572004,"preClose":0.58,"halted":0,"volume":84546,"delay":0,"changeRate":-0.0175862068965517,"floatShares":10202000,"shares":33414448,"eps":-1.9764,"marketStatus":"Trading","change":-0.0102,"latestTime":"06-10 12:11:30 EDT","open":0.56,"high":0.5817,"low":0.56,"amount":48554.21233278,"amplitude":0.037414,"askPrice":0.5699,"askSize":100,"bidPrice":0.5625,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.9764,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1781121600000},"marketStatusCode":2,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.58,"preHourTrading":{"tag":"盘前","latestPrice":0.5571,"preClose":0.58,"latestTime":"08:39 EDT","volume":9510,"amount":5298.968196,"timestamp":1781095151597,"change":-0.0229,"changeRate":-0.039483,"amplitude":0.039138},"postHourTrading":{"tag":"盘后","latestPrice":0.5916,"preClose":0.58,"latestTime":"18:43 EDT","volume":10021,"amount":5925.696,"timestamp":1781044984583,"change":0.0116,"changeRate":0.02,"amplitude":0.02},"volumeRatio":0.57714},"requestUrl":"/m/hq/s/KTTA/wiki","defaultTab":"wiki","newsList":[{"id":"2640891780","title":"Pasithea says FDA grants orphan drug designation for PAS-004 in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2640891780","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640891780?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:05","pubTimestamp":1780398337,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics received FDA Orphan Drug Designation for PAS-004 to treat amyotrophic lateral sclerosis.Designation could support development via tax credits, fee waivers, potential seven-year U.S. market exclusivity on approval.ALS Association awarded a USD 1 million grant in November 2025 to study PAS-004 in ALS.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL2hLZ1g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640912037","title":"Pasithea Therapeutics Announces Orphan Drug Designation by FDA of Pas-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640912037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640912037?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:02","pubTimestamp":1780398120,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA57Q0L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639717506","title":"Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2639717506","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639717506?lang=en_us&edition=fundamental","pubTime":"2026-05-30 01:55","pubTimestamp":1780077312,"startTime":"0","endTime":"0","summary":"The FDA granted Pasithea Therapeutics (KTTA) orphan designation for a treatment of amyotrophic lateral sclerosis, according to a post to the agency...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-gets-orphan-status-for-treatment-of-amyotrophic-lateral-sclerosis-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-gets-orphan-status-for-treatment-of-amyotrophic-lateral-sclerosis-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637409305","title":"Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?","url":"https://stock-news.laohu8.com/highlight/detail?id=2637409305","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637409305?lang=en_us&edition=fundamental","pubTime":"2026-05-24 20:12","pubTimestamp":1779624725,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ktta/pasithea-therapeutics/news/is-pasithea-therapeutics-nasdaqktta-in-a-good-position-to-de","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ktta/pasithea-therapeutics/news/is-pasithea-therapeutics-nasdaqktta-in-a-good-position-to-de","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637349382","title":"Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained","url":"https://stock-news.laohu8.com/highlight/detail?id=2637349382","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637349382?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:15","pubTimestamp":1779358550,"startTime":"0","endTime":"0","summary":"In a report released today, Sara Nik from H.C. Wainwright reiterated a Buy rating on Pasithea Therapeutics Corp, with a price target of $3.00. Sara...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pasithea-therapeutics-buy-rating-reiterated-on-pas-004-upside-potential-and-strong-cash-runway-3-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pasithea-therapeutics-buy-rating-reiterated-on-pas-004-upside-potential-and-strong-cash-runway-3-price-target-maintained-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635055355","title":"Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635055355","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635055355?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:22","pubTimestamp":1778883765,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (NASDAQ:KTTA) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.45) by 73.33 percent. This is a 92.55 percent increase over losses of $(1.61) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52620348/pasithea-therapeutics-q1-eps-0-12-beats-0-45-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635053604","title":"Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635053604","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635053604?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:41","pubTimestamp":1778881283,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp reports results for the quarter ended March 31 - Earnings SummaryPasithea Therapeutics Corp KTTA.OQ reported a quarterly adjusted loss of 12 cents per share for the quarter ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S27Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635803071","title":"Pasithea Therapeutics Corp  expected to post a loss of 45 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635803071","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635803071?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:41","pubTimestamp":1778877679,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp  expected to post a loss of45cents a share - Earnings Preview Pasithea Therapeutics Corp KTTA.OQ KTTA.O is expected to  report resultson May 18 (estimated) for the period en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S240:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635030255","title":"Pasithea net loss narrows 19.5% to $2.87 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030255","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030255?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:38","pubTimestamp":1778877529,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics posted a net loss of $2.87 million for the three months ended March 31, 2026, narrowing 19.5% from a year earlier.Operating loss widened 32.5% to $4.88 million, while research and development expense climbed 70.1% to $2.94 million.Other income rose to $2.01 million, driven by a $1.47 million increase in the change in fair value of warrant liabilities.Cash, cash equivalents and restricted cash fell $4.76 million during the quarter; working capital dipped to $51.24 million as of March 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLb3xMRb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634926255","title":"Pasithea Therapeutics Corp  expected to post a loss of 45 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634926255","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634926255?lang=en_us&edition=fundamental","pubTime":"2026-05-12 06:20","pubTimestamp":1778538007,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp  expected to post a loss of45cents a share - Earnings Preview Pasithea Therapeutics Corp KTTA.OQ KTTA.O is expected to  report resultson May 13 (estimated) for the period en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2RX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633924418","title":"Pasithea Therapeutics files Form 3 for Chief Medical Officer Kartik Krishnan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633924418","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633924418?lang=en_us&edition=fundamental","pubTime":"2026-05-06 04:46","pubTimestamp":1778013997,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics filed an initial Form 3 for Chief Medical Officer Kartik Krishnan dated May 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL4t8z1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633962077","title":"Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives","url":"https://stock-news.laohu8.com/highlight/detail?id=2633962077","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633962077?lang=en_us&edition=fundamental","pubTime":"2026-05-05 07:03","pubTimestamp":1777935785,"startTime":"0","endTime":"0","summary":"An announcement from Pasithea Therapeutics Corp ( ($KTTA) ) is now available. On May 4, 2026, Pasithea Therapeutics announced it had appointed Kart...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-appoints-new-cmo-updates-equity-incentives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-appoints-new-cmo-updates-equity-incentives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BK4215","KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632371769","title":"Pasithea Therapeutics names Kartik Krishnan chief medical officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2632371769","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632371769?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:05","pubTimestamp":1777892719,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics appointed Kartik Krishnan as chief medical officer, effective May 1, 2026.Krishnan will lead clinical development and medical strategy as PAS-004 advances in neurofibromatosis type 1 associated plexiform and cutaneous neurofibromas.He was previously CEO of OncoNano Medicines, following a stint as CMO at Arcus Biosciences.Earlier roles included clinical development and medical leadership positions at Genentech, BioMarin, Amgen, Astex Pharmaceuticals, and Five Prime Therapeutics.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL43sjMl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4599","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BKPKM429.USD","LU2112291526.USD","LU0122379950.USD","LU2242646821.SGD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","IE00B19Z3B42.SGD","IE0009355771.USD","LU2242652126.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU2089984988.USD","SG9999014039.USD","BK4112","LU2095319765.USD","LU0058720904.USD","LU1023059063.AUD","LU0868494617.USD","LU0889565916.HKD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4581","LU0320765992.SGD","IE00BN0W2T93.GBP","BK4566","IE00B2B36J28.USD","IE0002141913.USD","IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","IE00B7SZLL34.SGD","LU1983299246.USD","SG9999014005.SGD","BK4588","IE0002270589.USD","LU1571399168.USD","SG9999014013.SGD","BK4534","LU1057294990.SGD","LU2210150020.SGD","BK4533","SG9999001440.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00B19Z3581.USD","BK4139","IE00BN0W2V16.EUR","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629279997","title":"Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2629279997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629279997?lang=en_us&edition=fundamental","pubTime":"2026-04-21 00:37","pubTimestamp":1776703020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KTTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 20, 2026 12:37 ET (16:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742602","title":"Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742602","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742602?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:01","pubTimestamp":1776682860,"startTime":"0","endTime":"0","summary":"Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV)MIAMI, April  20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasith","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276869/0/en/Pasithea-Therapeutics-Announces-Grant-of-Rare-Pediatric-Disease-Designation-RPDD-by-FDA-to-PAS-004-for-Treatment-of-Neurofibromatosis-Type-1-NF1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","KTTA","LU1169590202.USD","LU1169589451.USD","BK4181","BK4139","BK4023","BK4096","BK4585","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628373304","title":"Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP","url":"https://stock-news.laohu8.com/highlight/detail?id=2628373304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628373304?lang=en_us&edition=fundamental","pubTime":"2026-04-18 09:45","pubTimestamp":1776476744,"startTime":"0","endTime":"0","summary":"Coastlands Capital LP filed Form 3 disclosing 10% ownership in Pasithea Therapeutics  tied to event date April 9, 2026.Filing shows indirect beneficial ownership of 3,735,035 shares of common stock.Coastlands also reported indirect ownership of pre-funded warrants exercisable for 11,233,334 shares at an exercise price of USD 0.001.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260418:nNDL6FCwLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624768715","title":"Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624768715","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624768715?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:01","pubTimestamp":1775163673,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings SummaryPasithea Therapeutics Corp KTTA.OQ reported a quarterly adjusted loss of 79 cents per share for the quart","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL8N40L21L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590888","title":"Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590888","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590888?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:01","pubTimestamp":1775041260,"startTime":"0","endTime":"0","summary":"Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266483/0/en/Pasithea-Therapeutics-Announces-Grant-of-Fast-Track-Designation-by-FDA-to-PAS-004-for-Treatment-of-Neurofibromatosis-Type-1-NF1-Associated-Plexiform-Neurofibromas-PN-Causing-Signif.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","BK4588","KTTA","LU1169589451.USD","BK4181","BK4139","BK4023","LU1169590202.USD","BK4585","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537335","title":"Pasithea Therapeutics Corp  expected to post a loss of 45 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537335","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537335?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:02","pubTimestamp":1774987340,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp  expected to post a loss of45cents a share - Earnings Preview Pasithea Therapeutics Corp KTTA.OQ KTTA.O is expected to  report resultson May 13 (estimated) for the period en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J2D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622277370","title":"Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2622277370","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622277370?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:09","pubTimestamp":1774433350,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ktta/pasithea-therapeutics/news/positive-signs-as-multiple-insiders-buy-pasithea-therapeutic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ktta/pasithea-therapeutics/news/positive-signs-as-multiple-insiders-buy-pasithea-therapeutic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pasithea.com","stockEarnings":[{"period":"1week","weight":-0.1008},{"period":"1month","weight":-0.2707},{"period":"3month","weight":-0.316},{"period":"6month","weight":-0.4821},{"period":"1year","weight":-0.3556},{"period":"ytd","weight":-0.5504}],"compareEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.0898},{"period":"6month","weight":0.0695},{"period":"1year","weight":0.2291},{"period":"ytd","weight":0.0808}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.182441},{"month":2,"riseRate":0.4,"avgChangeRate":-0.152614},{"month":3,"riseRate":0.4,"avgChangeRate":-0.0152},{"month":4,"riseRate":0.2,"avgChangeRate":0.004803},{"month":5,"riseRate":0.4,"avgChangeRate":-0.176425},{"month":6,"riseRate":0.4,"avgChangeRate":0.011834},{"month":7,"riseRate":1,"avgChangeRate":0.10295},{"month":8,"riseRate":0.5,"avgChangeRate":-0.003687},{"month":9,"riseRate":0.5,"avgChangeRate":-0.003936},{"month":10,"riseRate":0.2,"avgChangeRate":-0.132455},{"month":11,"riseRate":0.4,"avgChangeRate":0.147256},{"month":12,"riseRate":0.4,"avgChangeRate":-0.165941}],"exchange":"NASDAQ","name":"Pasithea Therapeutics Corp.","nameEN":"Pasithea Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pasithea Therapeutics Corp.,KTTA,Pasithea Therapeutics Corp.股票,Pasithea Therapeutics Corp.股票老虎,Pasithea Therapeutics Corp.股票老虎国际,Pasithea Therapeutics Corp.行情,Pasithea Therapeutics Corp.股票行情,Pasithea Therapeutics Corp.股价,Pasithea Therapeutics Corp.股市,Pasithea Therapeutics Corp.股票价格,Pasithea Therapeutics Corp.股票交易,Pasithea Therapeutics Corp.股票购买,Pasithea Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction